This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
immune response | 1019 |
type i | 767 |
immune responses | 749 |
innate immune | 708 |
respiratory syndrome | 682 |
acute respiratory | 650 |
dendritic cells | 599 |
nk cells | 570 |
virus infection | 567 |
influenza virus | 563 |
epithelial cells | 502 |
viral infections | 489 |
severe acute | 473 |
immune system | 465 |
viral infection | 428 |
immune cells | 398 |
cell responses | 385 |
inflammatory cytokines | 336 |
syndrome coronavirus | 334 |
severe covid | 300 |
i interferon | 296 |
innate immunity | 294 |
respiratory syncytial | 277 |
class i | 274 |
syncytial virus | 272 |
i ifn | 264 |
gene expression | 262 |
like receptor | 260 |
inflammatory response | 257 |
natural killer | 254 |
peripheral blood | 250 |
specific cd | 246 |
novel coronavirus | 244 |
viral replication | 235 |
cytokine storm | 234 |
infected cells | 228 |
respiratory tract | 227 |
mhc class | 223 |
nk cell | 223 |
coronavirus disease | 221 |
cd cd | 220 |
clinical trials | 218 |
adaptive immune | 215 |
lung injury | 213 |
front immunol | 202 |
multiple sclerosis | 198 |
neutralizing antibodies | 195 |
nlrp inflammasome | 188 |
mouse model | 186 |
viral rna | 185 |
high levels | 183 |
cell epitopes | 182 |
pulmonary disease | 180 |
signaling pathway | 176 |
th cells | 176 |
cell activation | 172 |
alveolar macrophages | 172 |
chronic obstructive | 170 |
like receptors | 170 |
cord uid | 167 |
doc id | 167 |
immunol doi | 167 |
cytokine production | 165 |
obstructive pulmonary | 164 |
middle east | 163 |
east respiratory | 162 |
cell response | 157 |
cell types | 157 |
airway epithelial | 156 |
supplementary material | 153 |
inflammatory responses | 150 |
signaling pathways | 148 |
antibody responses | 148 |
respiratory distress | 148 |
dendritic cell | 144 |
cell death | 144 |
important role | 143 |
animal models | 143 |
spike protein | 142 |
disease severity | 142 |
amino acid | 142 |
infectious diseases | 140 |
endothelial cells | 140 |
distress syndrome | 139 |
bone marrow | 139 |
monocytes macrophages | 134 |
trained immunity | 133 |
zika virus | 132 |
type diabetes | 131 |
memory cd | 130 |
necrosis factor | 129 |
influenza infection | 129 |
cell subsets | 129 |
virus replication | 128 |
viral load | 127 |
sars coronavirus | 127 |
intravenous immunoglobulin | 124 |
autoimmune diseases | 123 |
myeloid cells | 123 |
neutralizing antibody | 122 |
infected mice | 121 |
vaccine development | 121 |
host cell | 120 |
adaptive immunity | 120 |
may also | 119 |
cell surface | 119 |
monoclonal antibody | 119 |
inflammasome activation | 119 |
tumor necrosis | 119 |
mait cells | 117 |
monoclonal antibodies | 117 |
rna viruses | 117 |
host cells | 116 |
cell lines | 115 |
dipeptidyl peptidase | 115 |
antiviral response | 114 |
inflammatory cytokine | 114 |
host immune | 113 |
killer cells | 113 |
coronavirus infection | 112 |
iav infection | 112 |
viral clearance | 112 |
immune cell | 112 |
rsv infection | 111 |
rheumatoid arthritis | 111 |
oxidative stress | 111 |
dengue virus | 111 |
proinflammatory cytokines | 110 |
expression levels | 109 |
class ii | 109 |
stranded rna | 109 |
systematic review | 109 |
clinical trial | 108 |
transcription factor | 106 |
nervous system | 106 |
cell receptor | 105 |
united states | 104 |
ex vivo | 104 |
antiviral activity | 104 |
cov infection | 102 |
herpes simplex | 101 |
neutrophil extracellular | 99 |
influenza viruses | 99 |
airway epithelium | 98 |
copd patients | 97 |
potential conflict | 97 |
financial relationships | 97 |
human cd | 97 |
ifn production | 95 |
control group | 95 |
viral proteins | 95 |
stem cells | 94 |
significantly higher | 94 |
infected patients | 94 |
acute lung | 94 |
viral entry | 93 |
virus infections | 93 |
previously described | 92 |
central nervous | 91 |
antibody response | 91 |
protein kinase | 91 |
tissue damage | 91 |
diabetes mellitus | 91 |
simplex virus | 90 |
severe cases | 90 |
cytokine release | 90 |
transcription factors | 90 |
complement activation | 90 |
target cells | 89 |
flow cytometry | 89 |
authors declare | 89 |
critical role | 88 |
presenting cells | 88 |
ng ml | 88 |
nitric oxide | 87 |
risk factors | 87 |
mait cell | 87 |
increased levels | 87 |
haemophilus influenzae | 86 |
recent study | 86 |
specific antibodies | 86 |
disease progression | 86 |
deficient mice | 86 |
ifn signaling | 85 |
immunodeficiency virus | 85 |
plasma membrane | 85 |
lymph nodes | 85 |
killer cell | 84 |
cell line | 84 |
rna polymerase | 84 |
growth factor | 84 |
recognition receptors | 84 |
host defense | 84 |
healthy controls | 84 |
performed using | 84 |
lower respiratory | 84 |
converting enzyme | 83 |
ns protein | 83 |
cell proliferation | 83 |
extracellular traps | 83 |
amino acids | 83 |
phase i | 82 |
type iii | 82 |
plasmacytoid dendritic | 82 |
highly pathogenic | 82 |
epithelial cell | 81 |
respiratory virus | 81 |
respiratory viral | 81 |
accepted academic | 80 |
mononuclear cells | 80 |
cells via | 80 |
academic practice | 80 |
cell epitope | 80 |
ad vectors | 79 |
immunology www | 79 |
higher levels | 79 |
another study | 78 |
molecular mechanisms | 78 |
mouse models | 78 |
cigarette smoke | 78 |
severe disease | 78 |
antiviral responses | 78 |
lung tissue | 77 |
ms patients | 77 |
original publication | 77 |
original author | 76 |
side effects | 76 |
macrophage activation | 76 |
previous studies | 76 |
healthy individuals | 76 |
inhibitory receptors | 76 |
time points | 76 |
lung inflammation | 76 |
fatty acids | 76 |
effector functions | 76 |
structural proteins | 76 |
commons attribution | 75 |
cohort study | 75 |
bacterial infections | 75 |
regulatory factor | 75 |
copyright owner | 75 |
clinical characteristics | 75 |
lung disease | 75 |
stimulating factor | 75 |
data suggest | 75 |
dependent manner | 75 |
binding domain | 75 |
antigen presentation | 75 |
cell function | 75 |
pattern recognition | 75 |
creative commons | 75 |
porcine reproductive | 74 |
attribution license | 74 |
article distributed | 74 |
human coronavirus | 74 |
west nile | 73 |
based vaccines | 73 |
ifn response | 73 |
bronchial epithelial | 73 |
type ii | 73 |
cell populations | 73 |
critically ill | 73 |
endoplasmic reticulum | 73 |
taken together | 73 |
effector cells | 72 |
cell differentiation | 72 |
i interferons | 72 |
access article | 71 |
th responses | 71 |
stem cell | 71 |
respiratory infections | 70 |
blood mononuclear | 70 |
i molecules | 70 |
significantly reduced | 70 |
patients infected | 70 |
antiviral immunity | 70 |
live attenuated | 69 |
kawasaki disease | 69 |
cell therapy | 69 |
diabetic patients | 69 |
significantly increased | 69 |
pref alum | 69 |
syndrome virus | 69 |
human immunodeficiency | 68 |
inflammatory diseases | 68 |
increased risk | 68 |
cell population | 68 |
also found | 68 |
lncbst bispr | 68 |
major histocompatibility | 67 |
hla class | 67 |
airway inflammation | 67 |
adverse events | 67 |
cardiovascular disease | 67 |
recent studies | 66 |
cells may | 66 |
hiv infection | 65 |
tnf blockade | 65 |
nile virus | 65 |
rna virus | 65 |
lymphoid cells | 65 |
several studies | 65 |
immune signaling | 64 |
cell exhaustion | 64 |
spinal cord | 64 |
porcine epidemic | 64 |
immune activation | 64 |
interferon signaling | 64 |
lung diseases | 64 |
innate lymphoid | 64 |
histocompatibility complex | 63 |
public health | 63 |
sex hormones | 63 |
respiratory viruses | 63 |
retinoic acid | 63 |
avian influenza | 62 |
increased expression | 62 |
virus type | 62 |
sars patients | 62 |
protective immunity | 62 |
murine model | 62 |
young children | 62 |
i ifns | 62 |
bronchoalveolar lavage | 62 |
acute phase | 62 |
results showed | 62 |
ill patients | 62 |
mental health | 62 |
clinical features | 61 |
cell frequencies | 61 |
cellular immune | 61 |
mrna expression | 61 |
key role | 61 |
ttp ko | 61 |
differentially expressed | 61 |
bd biosciences | 60 |
viral titers | 60 |
significant differences | 60 |
epithelial barrier | 60 |
also known | 60 |
interferon regulatory | 60 |
ivig therapy | 60 |
staphylococcus aureus | 60 |
molecular patterns | 60 |
challenged ttp | 59 |
gut microbiota | 59 |
inflammatory mediators | 59 |
mice infected | 59 |
specific antibody | 59 |
nucleic acid | 59 |
cell type | 59 |
vaccine candidates | 59 |
cell culture | 59 |
respiratory failure | 59 |
cov infections | 58 |
clinical studies | 58 |
igg antibodies | 58 |
mesenchymal stem | 58 |
pregnant women | 58 |
peptidase iv | 58 |
infected individuals | 57 |
fatty acid | 57 |
epidemic diarrhea | 57 |
host factors | 57 |
sex differences | 57 |
streptococcus pneumoniae | 57 |
protective role | 56 |
pref advax | 56 |
chronic inflammatory | 56 |
i signaling | 56 |
lupus erythematosus | 56 |
antiviral signaling | 55 |
receptor binding | 55 |
systemic lupus | 55 |
cell immunity | 55 |
receptor signaling | 55 |
i activation | 55 |
respiratory disease | 55 |
th th | 55 |
hospitalized patients | 55 |
weight loss | 55 |
cd cells | 54 |
secondary bacterial | 54 |
lung cancer | 54 |
humoral immunity | 54 |
virus ns | 54 |
mg ml | 54 |
antiviral immune | 53 |
pulmonary fibrosis | 53 |
mortality rate | 53 |
antibody production | 53 |
antibody titers | 53 |
human lung | 53 |
cell entry | 53 |
signal transduction | 53 |
days post | 52 |
producing cd | 52 |
tumor cells | 52 |
associated molecular | 52 |
complement system | 52 |
interferon production | 52 |
tlr signaling | 52 |
ubiquitin ligase | 52 |
human airway | 52 |
specific igg | 52 |
sting pathway | 52 |
significantly decreased | 52 |
activated protein | 52 |
convalescent plasma | 52 |
bacterial infection | 51 |
cytokine expression | 51 |
lung damage | 51 |
treated mice | 51 |
highly expressed | 51 |
barr virus | 51 |
release syndrome | 51 |
low levels | 51 |
may contribute | 51 |
diarrhea virus | 50 |
innate antiviral | 50 |
inducible gene | 50 |
influenza vaccine | 50 |
serum levels | 50 |
autoimmune encephalomyelitis | 50 |
potential role | 50 |
intensive care | 50 |
infectious disease | 50 |
lymph node | 50 |
cancer patients | 50 |
binding protein | 50 |
humoral immune | 50 |
cells expressing | 50 |
controlled trial | 50 |
yellow fever | 50 |
adipose tissue | 50 |
ko mice | 50 |
significantly lower | 50 |
mumps virus | 49 |
expressed genes | 49 |
structural basis | 49 |
derived macrophages | 49 |
closely related | 49 |
mediated antiviral | 49 |
progenitor cells | 49 |
also observed | 49 |
extracellular vesicles | 49 |
interferon response | 49 |
experimental autoimmune | 49 |
dose ivig | 49 |
lung epithelial | 49 |
autoimmune disease | 48 |
cells infected | 48 |
receptor expression | 48 |
cancer cells | 48 |
elevated levels | 48 |
viral genome | 48 |
septic shock | 48 |
nuclear export | 48 |
th cell | 47 |
cells express | 47 |
herd immunity | 47 |
antigen receptor | 47 |
insulin resistance | 47 |
following infection | 47 |
stimulated genes | 47 |
human monoclonal | 47 |
statistically significant | 47 |
th response | 47 |
viral protein | 46 |
world health | 46 |
body weight | 46 |
sars cov | 46 |
myeloid cell | 46 |
iav infections | 46 |
knockout mice | 46 |
wide range | 46 |
virus vaccine | 46 |
membrane fusion | 46 |
reactive protein | 46 |
immune function | 46 |
significant increase | 46 |
immunized mice | 46 |
human cells | 46 |
nuclear factor | 46 |
present study | 46 |
vaccine design | 46 |
mediated immunity | 45 |
coronavirus infections | 45 |
chimeric antigen | 45 |
chronic inflammation | 45 |
nucleic acids | 45 |
gene therapy | 45 |
antiviral innate | 45 |
room temperature | 45 |
binding affinity | 45 |
authors contributed | 45 |
myocardial infarction | 45 |
antigen presenting | 45 |
patients compared | 45 |
mucosal immune | 45 |
cutting edge | 45 |
acute viral | 44 |
upper respiratory | 44 |
cell cycle | 44 |
may play | 44 |
lung pathology | 44 |
rabies virus | 44 |
breast cancer | 44 |
protein expression | 44 |
animal model | 44 |
ebola virus | 44 |
reactive oxygen | 44 |
signaling cascade | 44 |
pandemic influenza | 43 |
one study | 43 |
also demonstrated | 43 |
goat anti | 43 |
escherichia coli | 43 |
chikungunya virus | 43 |
supplementary table | 43 |
human respiratory | 43 |
siv infection | 43 |
tumor growth | 43 |
alveolar epithelial | 43 |
stat signaling | 43 |
expressing cells | 43 |
cell membrane | 43 |
terminal domain | 43 |
cord blood | 43 |
cell repertoire | 43 |
even though | 42 |
cancer immunotherapy | 42 |
lung function | 42 |
health organization | 42 |
helper cells | 42 |
lower levels | 42 |
adaptor protein | 42 |
coronavirus spike | 42 |
effector memory | 42 |
study showed | 42 |
bacterial pneumonia | 42 |
vaccine candidate | 42 |
case report | 42 |
air pollution | 42 |
inactivated vaccine | 42 |
wound healing | 42 |
japanese encephalitis | 42 |
malaria patients | 42 |
cell counts | 42 |
cell infiltration | 42 |
specific memory | 42 |
like protease | 42 |
vaccinia virus | 42 |
mycobacterium tuberculosis | 42 |
i responses | 42 |
human cytomegalovirus | 42 |
chronic viral | 42 |
cd foxp | 41 |
spike glycoprotein | 41 |
mumps vaccine | 41 |
cytosolic dna | 41 |
informed consent | 41 |
nontypeable haemophilus | 41 |
severe influenza | 41 |
described previously | 41 |
human dendritic | 41 |
net formation | 41 |
induced lung | 41 |
risk factor | 41 |
available online | 41 |
future studies | 41 |
rhesus macaques | 41 |
adoptive transfer | 41 |
control mice | 41 |
determine whether | 41 |
human monocytes | 41 |
clinical symptoms | 41 |
binding site | 41 |
dependent enhancement | 41 |
tlr agonists | 41 |
blood cells | 41 |
rlr signaling | 40 |
heavy chain | 40 |
oxygen species | 40 |
tumor microenvironment | 40 |
vesicular stomatitis | 40 |
transgenic mice | 40 |
lopinavir ritonavir | 40 |
negative control | 40 |
macrophage colony | 40 |
human blood | 40 |
viral loads | 40 |
mucus production | 40 |
cd tregs | 40 |
crucial role | 40 |
neuropathic pain | 40 |
first trimester | 40 |
downstream signaling | 40 |
encephalitis virus | 39 |
respiratory infection | 39 |
high level | 39 |
mediated signaling | 39 |
stomatitis virus | 39 |
cell subset | 39 |
two groups | 39 |
intestinal epithelial | 39 |
lymphocyte subsets | 39 |
analyzed using | 39 |
structural protein | 39 |
essential role | 39 |
regulatory cells | 39 |
antitumor activity | 39 |
lymphoid tissue | 39 |
long noncoding | 39 |
strand rna | 39 |
macrophage polarization | 39 |
immune evasion | 38 |
influenza vaccination | 38 |
tissue repair | 38 |
iii ifns | 38 |
healthy donors | 38 |
new coronavirus | 38 |
chronic infection | 38 |
human peripheral | 38 |
results suggest | 38 |
fatality rate | 38 |
lag cd | 38 |
mass spectrometry | 38 |
cytotoxic activity | 38 |
th cytokines | 38 |
host response | 38 |
antimicrobial peptides | 38 |
phase ii | 37 |
vertical transmission | 37 |
interferon responses | 37 |
nuclear translocation | 37 |
tr cells | 37 |
patients treated | 37 |
older adults | 37 |
i production | 37 |
may provide | 37 |
human immune | 37 |
increased susceptibility | 37 |
cell numbers | 37 |
human placenta | 37 |
chemokine receptor | 37 |
cytokine levels | 37 |
submitted version | 37 |
new insights | 37 |
mortality rates | 37 |
huh cells | 37 |
found online | 37 |
central role | 37 |
lavage fluid | 37 |
th cytokine | 36 |
severe sepsis | 36 |
western blot | 36 |
increased il | 36 |
lactic acid | 36 |
activation syndrome | 36 |
mice immunized | 36 |
rna helicase | 36 |
human il | 36 |
protease inhibitor | 36 |
statistical analysis | 36 |
multiple organ | 36 |
female mice | 36 |
human macrophages | 36 |
blood samples | 36 |
murine models | 36 |
itr cells | 36 |
icu patients | 36 |
different types | 36 |
fetal interface | 36 |
mitochondrial antiviral | 36 |
therapeutic strategies | 36 |
cells using | 35 |
full supplementary | 35 |
type lectin | 35 |
virus strain | 35 |
cells following | 35 |
light chain | 35 |
hematopoietic stem | 35 |
expression level | 35 |
fever virus | 35 |
host innate | 35 |
may lead | 35 |
restriction elements | 35 |
zinc deficiency | 35 |
cell memory | 35 |
tissue injury | 35 |
clinical outcomes | 35 |
systemic inflammation | 35 |
protective effects | 35 |
dna vaccines | 35 |
pulmonary inflammation | 35 |
immune thrombocytopenia | 35 |
cc protein | 35 |
linked polyubiquitination | 35 |
primary human | 35 |
induced ifn | 35 |
muc ac | 35 |
org articles | 35 |
ethics committee | 35 |
serine protease | 35 |
may result | 35 |
dna vaccine | 35 |
high affinity | 34 |
inflammatory cells | 34 |
ifv infection | 34 |
viral pathogens | 34 |
crude extract | 34 |
cell activity | 34 |
proinflammatory cytokine | 34 |
social isolation | 34 |
randomized controlled | 34 |
human monocyte | 34 |
potential therapeutic | 34 |
recipient mice | 34 |
protective effect | 34 |
alpha beta | 34 |
igg antibody | 34 |
allergic asthma | 34 |
severe patients | 34 |
different cell | 34 |
inflammatory monocytes | 34 |
inhibitory factor | 34 |
mast cells | 34 |
gut microbiome | 34 |
large number | 33 |
study demonstrated | 33 |
mice treated | 33 |
noncoding rna | 33 |
negative regulation | 33 |
three times | 33 |
disease course | 33 |
negative bacteria | 33 |
mediated immune | 33 |
subunit vaccines | 33 |
gcn pii | 33 |
pg ml | 33 |
tract infections | 33 |
tyrosine kinase | 33 |
disease virus | 33 |
molecular weight | 33 |
recent advances | 33 |
thermo fisher | 33 |
transgene expression | 33 |
genital tract | 33 |
major role | 33 |
fusion protein | 33 |
first line | 33 |
coding rnas | 33 |
alexa fluor | 33 |
epitope discovery | 33 |
highly conserved | 33 |
remains unclear | 33 |
antitumor immunity | 33 |
pulmonary pathology | 33 |
palmitoylated proteins | 33 |
primary cells | 33 |
previously reported | 33 |
transforming growth | 33 |
results show | 33 |
mer peptides | 33 |
host proteins | 33 |
vitro studies | 32 |
attenuated rabv | 32 |
barrier function | 32 |
therapeutic target | 32 |
early stage | 32 |
cell apoptosis | 32 |
long non | 32 |
prostate cancer | 32 |
cells within | 32 |
high risk | 32 |
survival rate | 32 |
induced il | 32 |
clinical signs | 32 |
antibody levels | 32 |
activated cd | 32 |
steady state | 32 |
coding genes | 32 |
acute infection | 32 |
significant difference | 32 |
western blotting | 32 |
seasonal influenza | 32 |
smooth muscle | 32 |
stat pathway | 32 |
mmr vaccine | 32 |
lps challenge | 32 |
clinical course | 32 |
cx cr | 32 |
pivotal role | 32 |
iga antibodies | 32 |
cd ro | 32 |
protein levels | 32 |
iii ifn | 32 |
bl mice | 31 |
live vaccines | 31 |
also showed | 31 |
adverse effects | 31 |
extracellular matrix | 31 |
virus disease | 31 |
inactivated vaccines | 31 |
saudi arabia | 31 |
expressing il | 31 |
complex class | 31 |
differential expression | 31 |
virus challenge | 31 |
antigen processing | 31 |
viral evasion | 31 |
coronavirus pneumonia | 31 |
cell migration | 31 |
following rsv | 31 |
helper cell | 31 |
healthy volunteers | 31 |
marine mammals | 31 |
therapeutic potential | 31 |
phagocytic activity | 31 |
associated protein | 31 |
mechanical ventilation | 31 |
alternative pathway | 31 |
macrophage migration | 31 |
cytotoxic cd | 31 |
two different | 31 |
microbial pathogens | 31 |
functional exhaustion | 31 |
cytokine il | 30 |
cells also | 30 |
vaccine efficacy | 30 |
macrophage responses | 30 |
cell effector | 30 |
phase trial | 30 |
cell depletion | 30 |
signaling protein | 30 |
time pcr | 30 |
cells treated | 30 |
whole blood | 30 |
dnk cells | 30 |
migration inhibitory | 30 |
encoding il | 30 |
associated coronavirus | 30 |
volume article | 30 |
data indicate | 30 |
cytokine responses | 30 |
immune dysregulation | 30 |
viral antigens | 30 |
mild cases | 30 |
dna viruses | 30 |
increased mortality | 30 |
tlr agonist | 30 |
th immune | 30 |
statistical significance | 30 |
better understanding | 30 |
recent years | 30 |
kidney injury | 30 |
well plates | 30 |
also contribute | 30 |
healthy adults | 30 |
cell receptors | 30 |
respiratory epithelial | 29 |
human coronaviruses | 29 |
cells compared | 29 |
measles virus | 29 |
pathogenic avian | 29 |
lymphoid tissues | 29 |
like particles | 29 |
rna pol | 29 |
based vaccine | 29 |
important roles | 29 |
studies suggest | 29 |
dna methylation | 29 |
broad spectrum | 29 |
day post | 29 |
studies using | 29 |
gene i | 29 |
icf syndrome | 29 |
mechanisms underlying | 29 |
early phase | 29 |
effector function | 29 |
open reading | 29 |
click chemistry | 29 |
interferon induction | 29 |
hpa axis | 29 |
pathogenic role | 29 |
cell clones | 29 |
brain barrier | 29 |
lymphoid organs | 29 |
viral control | 29 |
antiviral effects | 29 |
inflammatory conditions | 29 |
high dose | 29 |
plasma levels | 29 |
rna binding | 29 |
care unit | 29 |
vaccine strain | 29 |
phase clinical | 29 |
cell development | 29 |
crystal structure | 29 |
genes involved | 29 |
dm patients | 29 |
time point | 29 |
card domains | 29 |
human igg | 29 |
cutaneous leishmaniasis | 29 |
vaccination strategies | 29 |
mammalian cells | 28 |
environmental factors | 28 |
adult mice | 28 |
results indicate | 28 |
severe respiratory | 28 |
secondary antibodies | 28 |
antimicrobial peptide | 28 |
tnf production | 28 |
antiviral drugs | 28 |
cell rna | 28 |
infection may | 28 |
protein palmitoylation | 28 |
oxide synthase | 28 |
palmitic acid | 28 |
inflammatory bowel | 28 |
interferon gamma | 28 |
like cells | 28 |
total rna | 28 |
cytokines il | 28 |
membrane protein | 28 |
dependent rna | 28 |
respiratory diseases | 28 |
ace receptor | 28 |
immunoglobulin therapy | 28 |
cytokine secretion | 28 |
immune repertoire | 28 |
leishmania major | 28 |
serum samples | 28 |
lysis buffer | 28 |
fisher scientific | 28 |
ifn induction | 28 |
dc subsets | 28 |
broadly neutralizing | 28 |
dna damage | 28 |
bacterial clearance | 28 |
virus entry | 28 |
high expression | 28 |
previous study | 28 |
viral titer | 28 |
endothelial cell | 28 |
suppressor cells | 28 |
lung microbiome | 28 |
tnf receptor | 28 |
severe pneumonia | 28 |
associated lymphoid | 28 |
gender differences | 28 |
producing cells | 28 |
ttp myeko | 28 |
blood monocytes | 28 |
viral vectors | 27 |
analysis showed | 27 |
following viral | 27 |
bacterial vaginosis | 27 |
written informed | 27 |
immune complexes | 27 |
copy number | 27 |
prospective study | 27 |
whole virus | 27 |
alveolar macrophage | 27 |
culture supernatants | 27 |
chronic hepatitis | 27 |
cd expression | 27 |
cellular immunity | 27 |
coated beads | 27 |
viral vector | 27 |
early stages | 27 |
sendai virus | 27 |
human primates | 27 |
human bronchial | 27 |
bovine serum | 27 |
linked ubiquitination | 27 |
coronary artery | 27 |
challenged wt | 27 |
case fatality | 27 |
chikv infection | 27 |
neonatal mice | 27 |
bcg vaccination | 27 |
mice lacking | 27 |
subunit vaccine | 27 |
many viruses | 27 |
mild covid | 27 |
also involved | 27 |
enveloped viruses | 27 |
irf activation | 27 |
single cell | 27 |
iav replication | 27 |
restricted cd | 27 |
intratumoral injection | 27 |
goblet cell | 27 |
widely used | 26 |
underlying mechanisms | 26 |
expression profiles | 26 |
related apoptosis | 26 |
possible role | 26 |
muscle cells | 26 |
fluorescent beads | 26 |
inducing ligand | 26 |
treg cells | 26 |
plasma cells | 26 |
among others | 26 |
white matter | 26 |
produce il | 26 |
binding proteins | 26 |
reading frame | 26 |
beneficial effects | 26 |
recombinant adenovirus | 26 |
phase iii | 26 |
foxp cd | 26 |
hepatitis virus | 26 |
lipid metabolism | 26 |
nucleocapsid protein | 26 |
analysis revealed | 26 |
high mortality | 26 |
viral shedding | 26 |
factor alpha | 26 |
inflammatory markers | 26 |
jev infection | 26 |
produce ifn | 26 |
viral diseases | 26 |
melanoma differentiation | 26 |
immunological toolbox | 26 |
activation markers | 26 |
significantly different | 26 |
bat species | 26 |
cells play | 26 |
disease control | 26 |
binding sites | 26 |
inflammatory disease | 26 |
draining lymph | 26 |
negative regulator | 26 |
viral particles | 26 |
positive control | 25 |
neutrophil activation | 25 |
also induced | 25 |
family members | 25 |
red blood | 25 |
therapeutic targets | 25 |
protease inhibitors | 25 |
th immunity | 25 |
clinical manifestations | 25 |
oral administration | 25 |
significant reduction | 25 |
cd dim | 25 |
organ dysfunction | 25 |
wt rabv | 25 |
serum il | 25 |
viral envelope | 25 |
cd bright | 25 |
infection induces | 25 |
liver disease | 25 |
acute kidney | 25 |
dose intravenous | 25 |
immune defense | 25 |
therapeutic approach | 25 |
spike proteins | 25 |
alu elements | 25 |
pseudomonas aeruginosa | 25 |
increased production | 25 |
flow cytometric | 25 |
complete regression | 25 |
platelet activation | 25 |
wt mice | 25 |
metabolic pathways | 25 |
immune homeostasis | 25 |
way anova | 25 |
cell functions | 25 |
passive immunization | 25 |
male mice | 25 |
tlr activation | 25 |
cytomegalovirus infection | 25 |
signal peptide | 25 |
chadox ncov | 25 |
enrichment analysis | 25 |
lung infection | 25 |
including il | 25 |
organ failure | 25 |
bowel disease | 25 |
ifn responses | 25 |
duck primary | 25 |
adenoviral vector | 25 |
hcv patients | 25 |
beta interferon | 25 |
hong kong | 25 |
follicular helper | 25 |
findings suggest | 25 |
antiviral defense | 25 |
stromal cell | 25 |
study found | 25 |
inflammatory effects | 25 |
tumor regression | 25 |
data analysis | 24 |
zikv infection | 24 |
cystic fibrosis | 24 |
reverse transcription | 24 |
regulatory cd | 24 |
recombinant protein | 24 |
adenovirus vector | 24 |
gastrointestinal tract | 24 |
viral pathogenesis | 24 |
disease pathogenesis | 24 |
human rhinovirus | 24 |
localized il | 24 |
human natural | 24 |
clinical data | 24 |
adhesion molecule | 24 |
jak stat | 24 |
resident macrophages | 24 |
solid tumors | 24 |
higher risk | 24 |
studies demonstrated | 24 |
will discuss | 24 |
cells induced | 24 |
idiopathic pulmonary | 24 |
immunomodulatory effects | 24 |
factors associated | 24 |
like protein | 24 |
may explain | 24 |
hcv infection | 24 |
throughput sequencing | 24 |
infected pneumonia | 24 |
cleavage site | 24 |
graphpad prism | 24 |
type immune | 24 |
severe sars | 24 |
chronic lung | 24 |
san diego | 24 |
skeletal muscle | 24 |
cerebrospinal fluid | 24 |
orally administered | 24 |
recent report | 24 |
barr body | 24 |
also shown | 24 |
microglial cells | 24 |
mice compared | 24 |
stimulated gene | 24 |
still unclear | 24 |
stromal cells | 24 |
mg kg | 24 |
inflammatory monocyte | 24 |
immune regulation | 24 |
increased survival | 24 |
negatively regulates | 24 |
membrane proteins | 24 |
host protein | 24 |
viral respiratory | 24 |
extract containing | 24 |
plasmodium falciparum | 24 |
poor prognosis | 24 |
surface expression | 24 |
vaccine failure | 24 |
systemic inflammatory | 23 |
factor receptor | 23 |
lung cells | 23 |
tlr expression | 23 |
myeloid dendritic | 23 |
current study | 23 |
influenza vaccines | 23 |
immune mechanisms | 23 |
angiotensin system | 23 |
cd effector | 23 |
cd regulatory | 23 |
sensor rig | 23 |
chronically infected | 23 |
virus neutralization | 23 |
memory cells | 23 |
cellular antiviral | 23 |
mrna vaccines | 23 |
patients showed | 23 |
viral mrna | 23 |
copd exacerbations | 23 |
target genes | 23 |
lung viral | 23 |
mhc molecules | 23 |
large amounts | 23 |
tgev infection | 23 |
protein interactions | 23 |
peptide epitopes | 23 |
better understand | 23 |
protects mice | 23 |
reduced viral | 23 |
induced apoptosis | 23 |
human health | 23 |
severe lung | 23 |
inflammatory signaling | 23 |
following i | 23 |
invading pathogens | 23 |
virus induces | 23 |
protein inhibits | 23 |
circulating monocytes | 23 |
foxp regulatory | 23 |
single dose | 23 |
urgent need | 23 |
total number | 23 |
listeria monocytogenes | 23 |
toxoplasma gondii | 23 |
wild type | 23 |
cxcl cxcr | 23 |
activated macrophages | 23 |
combination treatment | 23 |
randomized clinical | 23 |
receptor cd | 23 |
vital role | 23 |
hcmv infection | 23 |
early life | 23 |
lung macrophages | 23 |
rna viral | 23 |
viral dna | 23 |
deleterious effects | 23 |
protective immune | 23 |
cell subpopulations | 23 |
disease caused | 23 |
might contribute | 23 |
human leukocyte | 23 |
ifn pathway | 23 |
low level | 23 |
mice brain | 23 |
similar results | 22 |
interferon alpha | 22 |
reduced expression | 22 |
cytokine signaling | 22 |
ifnar signaling | 22 |
cellular processes | 22 |
mitochondrial dysfunction | 22 |
rna recognition | 22 |
nuclear import | 22 |
matrix protein | 22 |
also lead | 22 |
inflammatory lung | 22 |
global health | 22 |
cell cytotoxicity | 22 |
following immunization | 22 |
least one | 22 |
one hand | 22 |
mumps outbreaks | 22 |
cell signaling | 22 |
coding rna | 22 |
intracellular cytokine | 22 |
barrier integrity | 22 |
two patients | 22 |
polymerase iii | 22 |
cell expansion | 22 |
type mice | 22 |
prolyl endopeptidase | 22 |
effective treatment | 22 |
following respiratory | 22 |
mouse igg | 22 |
transmembrane domain | 22 |
ad vector | 22 |
increasing evidence | 22 |
also reported | 22 |
cell adhesion | 22 |
positively correlated | 22 |
via activation | 22 |
total cd | 22 |
rabbit anti | 22 |
igg concentrates | 22 |
studies involving | 22 |
cell immune | 22 |
intracellular pathogens | 22 |
causative agent | 22 |
nthi infection | 22 |
pilot study | 22 |
studies will | 22 |
thermo scientific | 22 |
cytokine profiles | 22 |
small molecule | 22 |
also associated | 22 |
interstitial lung | 22 |
ubiquitin ligases | 22 |
blood vessels | 22 |
ace expression | 22 |
protein synthesis | 22 |
viral immunity | 22 |
rhinovirus infection | 22 |
androgen receptor | 22 |
virus protein | 22 |
hepatocellular carcinoma | 22 |
generation sequencing | 22 |
retrospective cohort | 22 |
blood group | 22 |
molecular mechanism | 22 |
induced inflammation | 22 |
first time | 22 |
recovered patients | 22 |
mediated inflammatory | 22 |
mumps infection | 22 |
cd stimulation | 22 |
donor yf | 22 |
cells human | 22 |
lower airway | 21 |
expressing cd | 21 |
recombinant il | 21 |
related genes | 21 |
several viral | 21 |
mm nacl | 21 |
trimeric coe | 21 |
pathogen interactions | 21 |
fgl expression | 21 |
induced gene | 21 |
immune checkpoint | 21 |
blood cell | 21 |
campylobacter jejuni | 21 |
igm antibodies | 21 |
recombinant human | 21 |
candidate vaccines | 21 |
positive feedback | 21 |
sequencing data | 21 |
protein structure | 21 |
novel human | 21 |
asthma exacerbations | 21 |
may represent | 21 |
study design | 21 |
cell interactions | 21 |
many studies | 21 |
lung parenchyma | 21 |
angiotensin converting | 21 |
derived factor | 21 |
mediated protection | 21 |
cell wall | 21 |
young adults | 21 |
kidney disease | 21 |
mouse cd | 21 |
disease patients | 21 |
parainfluenza virus | 21 |
following influenza | 21 |
pathogen recognition | 21 |
small intestine | 21 |
adhesion molecules | 21 |
host macrophages | 21 |
kir ds | 21 |
semliki forest | 21 |
antibodies targeting | 21 |
pathogenic human | 21 |
janus kinase | 21 |
life cycle | 21 |
signaling via | 21 |
lymphocyte ratio | 21 |
card domain | 21 |
express il | 21 |
microbial communities | 21 |
emerging infectious | 21 |
target cell | 21 |
three different | 21 |
tract infection | 21 |
immune dysfunction | 21 |
family member | 21 |
infection model | 21 |
expression patterns | 21 |
negatively regulate | 21 |
genomic rna | 21 |
cell biology | 21 |
mediated activation | 21 |
cell stimulatory | 21 |
severely ill | 21 |
mucosal immunity | 21 |
human metapneumovirus | 21 |
atpase activity | 21 |
experimental models | 21 |
proteasomal degradation | 21 |
prolyl oligopeptidase | 21 |
reverse immunology | 21 |
transmissible gastroenteritis | 21 |
viral antigen | 21 |
ms lesions | 21 |
positive cells | 21 |
effective vaccine | 21 |
infectious tolerance | 20 |
nkt cells | 20 |
mediterranean fever | 20 |
high frequency | 20 |
vaccinated mice | 20 |
infected animals | 20 |
defense mechanisms | 20 |
retrospective study | 20 |
loaded microspheres | 20 |
nonstructural proteins | 20 |
cov replication | 20 |
virus particles | 20 |
human placental | 20 |
virus hemagglutinin | 20 |
commensal bacteria | 20 |
allergic inflammation | 20 |
protein interaction | 20 |
study reported | 20 |
familial mediterranean | 20 |
vaccine vectors | 20 |
evidence suggests | 20 |
acute infections | 20 |
plasmid dna | 20 |
sting signaling | 20 |
mavs signaling | 20 |
cell survival | 20 |
immune functions | 20 |
pd lag | 20 |
iii interferons | 20 |
expression analysis | 20 |
cd treg | 20 |
also plays | 20 |
alveolar damage | 20 |
zinc levels | 20 |
enhanced disease | 20 |
accessory proteins | 20 |
patients receiving | 20 |
macrophage cell | 20 |
metabolic disorders | 20 |
rna sensor | 20 |
plga nanoparticles | 20 |
cell maturation | 20 |
receptor antagonist | 20 |
preclinical studies | 20 |
mhc i | 20 |
controlled trials | 20 |
containing protein | 20 |
control study | 20 |
iii interferon | 20 |
human influenza | 20 |
pedv infection | 20 |
extracellular trap | 20 |
ifn expression | 20 |
human disease | 20 |
mediated neutralization | 20 |
associated pneumonia | 20 |
mumps outbreak | 20 |
cells produce | 20 |
derived dendritic | 20 |
human population | 20 |
adenovirus type | 20 |
new therapeutic | 20 |
significant changes | 20 |
ii clinical | 20 |
recently shown | 20 |
human cord | 20 |
units ml | 20 |
among patients | 20 |
specific iga | 20 |
antiviral state | 20 |
observational study | 20 |
associated genes | 20 |
higher expression | 20 |
genes associated | 20 |
expression pattern | 20 |
i pathway | 20 |
cxcr signaling | 20 |
viral pneumonia | 20 |
cd monocytes | 20 |
infected ferrets | 20 |
time course | 20 |
signal transducer | 20 |
i card | 20 |
therapeutic approaches | 20 |
leukocyte antigen | 20 |
mm tris | 20 |
cell carcinoma | 20 |
derived suppressor | 20 |
humoral response | 20 |
influenza pandemic | 20 |
core protein | 20 |
studies indicate | 20 |
refined models | 19 |
complement factor | 19 |
rna synthesis | 19 |
immune tolerance | 19 |
mice following | 19 |
pathological findings | 19 |
host immunity | 19 |
suppressive activity | 19 |
corona virus | 19 |
fat diet | 19 |
molecule inhibitors | 19 |
veterinary immunology | 19 |
years ago | 19 |
metabolic syndrome | 19 |
reagent development | 19 |
viral rnas | 19 |
i ubiquitination | 19 |
also play | 19 |
white blood | 19 |
multiple studies | 19 |
commercially available | 19 |
well plate | 19 |
chronic diseases | 19 |
expression profile | 19 |
pregsure bvd | 19 |
much lower | 19 |
age groups | 19 |
growth factors | 19 |
adenovirus serotype | 19 |
th differentiation | 19 |
gamma interferon | 19 |
animal care | 19 |
study also | 19 |
macrophage function | 19 |
humoral responses | 19 |
buffered saline | 19 |
mouse lung | 19 |
amp synthase | 19 |
antibody repertoire | 19 |
studies showed | 19 |
light chains | 19 |
acute exacerbations | 19 |
comparative analysis | 19 |
type responses | 19 |
among different | 19 |
dna sensing | 19 |
induced pulmonary | 19 |
acute exacerbation | 19 |
current knowledge | 19 |
interferon genes | 19 |
thrombocytopenic purpura | 19 |
responses following | 19 |
complement pathway | 19 |
inflammatory state | 19 |
tumor immunity | 19 |
trend toward | 19 |
colony stimulating | 19 |
clinical benefit | 19 |
within days | 19 |
specific immune | 19 |
prophylactic activity | 19 |
positive correlation | 19 |
article supplementary | 19 |
secretory iga | 19 |
house dust | 19 |
also able | 19 |
liver damage | 19 |
vascular permeability | 19 |
cancer therapy | 19 |
wide variety | 19 |
cells promote | 19 |
marburg virus | 19 |
host responses | 19 |
via tlr | 19 |
different hla | 19 |
molecular basis | 19 |
positive selection | 19 |
viral challenge | 19 |
data show | 19 |
conformational change | 19 |
cd ra | 19 |
secondary antibody | 19 |
antibiotic resistance | 19 |
chemokine receptors | 19 |
cytokines including | 19 |
human genome | 19 |
microbial infections | 19 |
inhibits type | 19 |
hb cells | 19 |
ns proteins | 19 |
promoter activity | 19 |
infected macaques | 19 |
patients suffering | 19 |
virus pathogenesis | 19 |
lung tissues | 19 |
inflammatory reactions | 19 |
fungal infections | 19 |
vaccine constructs | 19 |
ovarian cancer | 19 |
also detected | 19 |
associated invariant | 19 |
checkpoint inhibitors | 19 |
inflammatory process | 19 |
cyclic gmp | 19 |
negative feedback | 19 |
helicase domain | 19 |
mrna levels | 19 |
also present | 19 |
transmembrane proteins | 19 |
human ace | 19 |
binding lectin | 19 |
dust mite | 19 |
asthma patients | 19 |
chikv infected | 19 |
statistical analyses | 18 |
neutrophil infiltration | 18 |
beneficial effect | 18 |
ctl epitopes | 18 |
ii molecules | 18 |
pathway activation | 18 |
tumor antigen | 18 |
neonatal pancytopenia | 18 |
suppressive function | 18 |
manufacturing process | 18 |
cell sorting | 18 |
comprehensive review | 18 |
alum immunization | 18 |
diabetic mice | 18 |
clinical disease | 18 |
allergic airway | 18 |
immune recognition | 18 |
bacterial superinfection | 18 |
antibiotic treatment | 18 |
genes related | 18 |
cell stimulation | 18 |
increased viral | 18 |
jhmv infection | 18 |
many different | 18 |
type cytokines | 18 |
heart failure | 18 |
infection via | 18 |
human alveolar | 18 |
inducible factor | 18 |
cell cultures | 18 |
clinical efficacy | 18 |
acid sequence | 18 |
two distinct | 18 |
respiratory pathogens | 18 |
another important | 18 |
pulmonary hypertension | 18 |
antimicrobial activity | 18 |
stromal lymphopoietin | 18 |
reactive cd | 18 |
protective efficacy | 18 |
vector expressing | 18 |
chemokine ligand | 18 |
associated gene | 18 |
cov spike | 18 |
rna sensing | 18 |
dna sensor | 18 |
id cows | 18 |
study using | 18 |
may increase | 18 |
protein ns | 18 |
neutrophil recruitment | 18 |
direct interaction | 18 |
host rna | 18 |
several clinical | 18 |
brain injury | 18 |
thrombus formation | 18 |
langerhans cells | 18 |
rsv challenge | 18 |
primary antibodies | 18 |
immune stimulation | 18 |
reduced lung | 18 |
conformational changes | 18 |
fc receptor | 18 |
control groups | 18 |
intranasal administration | 18 |
current status | 18 |
viral disease | 18 |
pref alone | 18 |
rna sequencing | 18 |
results indicated | 18 |
immune systems | 18 |
determined using | 18 |
mediated inhibition | 18 |
alloimmune thrombocytopenia | 18 |
may promote | 18 |
variable regions | 18 |
primary infection | 18 |
mast cell | 18 |
tmp peptide | 18 |
uninfected cells | 18 |
limited number | 18 |
particulate matter | 18 |
bottlenose dolphins | 18 |
pulmonary infections | 18 |
dependent innate | 18 |
electron microscopy | 18 |
fold change | 18 |
bovine neonatal | 18 |
datasets generated | 18 |
thrombotic events | 18 |
male sex | 18 |
common cold | 18 |
cfhr deletion | 18 |
healthy children | 18 |
dependent cell | 18 |
several factors | 18 |
secondary lymphoid | 18 |
bcg vaccine | 18 |
peripheral mait | 18 |
recently demonstrated | 18 |
vrnp complex | 18 |
mediated cytotoxicity | 18 |
conjugated goat | 18 |
serious adverse | 18 |
patients may | 18 |
high glucose | 18 |
domain antibodies | 18 |
noncoding rnas | 18 |
virulent strain | 18 |
specific immunity | 18 |
dependent activation | 18 |
response induced | 18 |
general population | 18 |
safety profile | 18 |
bacterial colonization | 18 |
peptide binding | 18 |
effector cd | 18 |
express high | 18 |
stimulated cd | 18 |
specific effector | 18 |
thymic stromal | 18 |
maturation pathways | 18 |
naturally occurring | 18 |
induced inflammatory | 18 |
chlamydia trachomatis | 18 |
gastroenteritis virus | 18 |
human infection | 17 |
immune status | 17 |
related protein | 17 |
extensively studied | 17 |
positive regulator | 17 |
therapeutic interventions | 17 |
dna virus | 17 |
genomic copy | 17 |
may induce | 17 |
expression vector | 17 |
local immune | 17 |
angiotensin ii | 17 |
severe coronavirus | 17 |
unclear whether | 17 |
receptor complex | 17 |
inflammatory cell | 17 |
cell recruitment | 17 |
genetically modified | 17 |
therapeutic strategy | 17 |
cell mediated | 17 |
age group | 17 |
net release | 17 |
nerve injury | 17 |
attenuated vaccines | 17 |
i trial | 17 |
vaccine platforms | 17 |
virus vaccines | 17 |
dependent mechanism | 17 |
iga antibody | 17 |
cytosolic rna | 17 |
severe viral | 17 |
alveolar type | 17 |
two main | 17 |
lung sections | 17 |
recent data | 17 |
higher mortality | 17 |
uric acid | 17 |
also increased | 17 |
promising results | 17 |
previously shown | 17 |
national health | 17 |
bacterial pathogens | 17 |
asthma development | 17 |
nadph oxidase | 17 |
inflammatory processes | 17 |
innate response | 17 |
cell transplantation | 17 |
specific cell | 17 |
th effector | 17 |
nonhuman primates | 17 |
infected macrophages | 17 |
interferon beta | 17 |
treatment options | 17 |
neutrophil adhesion | 17 |
i clinical | 17 |
chronic stress | 17 |
fold higher | 17 |
vaccinated group | 17 |
ge healthcare | 17 |
poorly understood | 17 |
cardiovascular diseases | 17 |
like il | 17 |
also induces | 17 |
mycoplasma infections | 17 |
immunopathology following | 17 |
randomized trial | 17 |
mm edta | 17 |
primary immunodeficiency | 17 |
induced immune | 17 |
coronavirus vaccine | 17 |
disease activity | 17 |
health care | 17 |
dna sensors | 17 |
measured using | 17 |
therapeutic intervention | 17 |
three groups | 17 |
trail signaling | 17 |
tlr ligands | 17 |
obese patients | 17 |
discovery rate | 17 |
granulocyte macrophage | 17 |
airway remodeling | 17 |
beta production | 17 |
tissue sections | 17 |
cells control | 17 |
induced ali | 17 |
binding motif | 17 |
immune sensing | 17 |
pemphigus vulgaris | 17 |
also important | 17 |
functional receptor | 17 |
signaling cascades | 17 |
pbs controls | 17 |
showed increased | 17 |
viral immune | 17 |
specific cytotoxic | 17 |
without affecting | 17 |
hyperferritinemic syndrome | 17 |
proinflammatory mediators | 17 |
er membrane | 17 |
commonly used | 17 |
peripheral cd | 17 |
antibody titres | 17 |
will provide | 17 |
dpp inhibition | 17 |
cell phenotype | 17 |
vascular endothelial | 17 |
later time | 17 |
viral dsrna | 17 |
inducible nitric | 17 |
adenoviral vectors | 17 |
helper type | 17 |
advanced glycation | 17 |
antibody titer | 16 |
activation via | 16 |
hydrogen bonds | 16 |
inflammatory reaction | 16 |
enzymatic activity | 16 |
also identified | 16 |
animal studies | 16 |
natural infection | 16 |
storm syndromes | 16 |
virally infected | 16 |
cytokine profile | 16 |
finger protein | 16 |
bystander cells | 16 |
alternatively activated | 16 |
lower airways | 16 |
tcr repertoire | 16 |
ion channel | 16 |
pol iii | 16 |
neonatal alloimmune | 16 |
igg concentrate | 16 |
upregulated genes | 16 |
mice showed | 16 |
cd mab | 16 |
vaccine adjuvants | 16 |
several viruses | 16 |
raw cells | 16 |
feedback loop | 16 |
first case | 16 |
mitochondrial dna | 16 |
trophoblast cells | 16 |
data collection | 16 |
cell priming | 16 |
decreased expression | 16 |
mice group | 16 |
mouse serum | 16 |
mediated inflammation | 16 |
i response | 16 |
studies show | 16 |
xcr dcs | 16 |
clinical evidence | 16 |
veterinary immunological | 16 |
cells contribute | 16 |
clinical outcome | 16 |
forest virus | 16 |
specific igm | 16 |
treated group | 16 |
late stage | 16 |
resident memory | 16 |
isg expression | 16 |
hemophagocytic lymphohistiocytosis | 16 |
density lipoprotein | 16 |
herpes virus | 16 |
neonatal immune | 16 |
three patients | 16 |
rna genome | 16 |
target antigen | 16 |
mouse anti | 16 |
serine proteases | 16 |
motif chemokine | 16 |
play important | 16 |
probably due | 16 |
vast majority | 16 |
clinical practice | 16 |
dependent pathway | 16 |
sting activation | 16 |
cellular functions | 16 |
encephalomyocarditis virus | 16 |
i binding | 16 |
culture supernatant | 16 |
high viral | 16 |
three independent | 16 |
induce cd | 16 |
polyunsaturated fatty | 16 |
animal experiments | 16 |
immune suppression | 16 |
polymerase chain | 16 |
will also | 16 |
gene delivery | 16 |
invariant chain | 16 |
cell lysates | 16 |
cells including | 16 |
infections caused | 16 |
likely due | 16 |
human participants | 16 |
immune memory | 16 |
randomised controlled | 16 |
inflammatory properties | 16 |
human nk | 16 |
relatively low | 16 |
gs cells | 16 |
nuclear localization | 16 |
lethal influenza | 16 |
immune genes | 16 |
grade inflammation | 16 |
respiratory illness | 16 |
increased morbidity | 16 |
animal study | 16 |
surface antigens | 16 |
detected using | 16 |
virus clearance | 16 |
excess mortality | 16 |
infected astrocytes | 16 |
might also | 16 |
cytokine chemokine | 16 |
cellular responses | 16 |
per well | 16 |
post infection | 16 |
lung nk | 16 |
low dose | 16 |
case series | 16 |
critical roles | 16 |
chronic hcv | 16 |
corresponding author | 16 |
different time | 16 |
dysregulated type | 16 |
valproic acid | 16 |
mice bearing | 16 |
ha head | 16 |
involving human | 16 |
ctl responses | 16 |
coronavirus vaccines | 16 |
viral persistence | 16 |
data showed | 16 |
ii cells | 16 |
viral membrane | 16 |
use committee | 16 |
cell dysfunction | 16 |
preliminary report | 16 |
ros production | 16 |
potential target | 16 |
viral hepatitis | 16 |
receptor ace | 16 |
two types | 16 |
cellular stress | 16 |
elderly patients | 16 |
associated macrophages | 16 |
cells cd | 16 |
mucosal surfaces | 16 |
several mechanisms | 16 |
induced acute | 16 |
receptor repertoire | 16 |
type interferon | 16 |
false discovery | 16 |
consider cytokine | 16 |
chimpanzee adenovirus | 16 |
chain reaction | 16 |
severe infection | 16 |
highly vaccinated | 16 |
patients hospitalized | 16 |
severe vs | 16 |
lung immunopathology | 16 |
coronavirus nucleocapsid | 16 |
various cytokines | 16 |
inhibitory effects | 16 |
fetal bovine | 16 |
aged mice | 16 |
following vaccination | 16 |
live virus | 16 |
production via | 16 |
clinically proven | 16 |
inflammatory factors | 16 |
molecular cloning | 15 |
clinical use | 15 |
high titers | 15 |
arginase activity | 15 |
subcellular localization | 15 |
viral components | 15 |
phylogenetic analysis | 15 |
dpv infection | 15 |
inflammatory profile | 15 |
activate rig | 15 |
cells induce | 15 |
intracellular signaling | 15 |
fr nps | 15 |
recently reported | 15 |
ibalt areas | 15 |
bal fluid | 15 |
infectious agent | 15 |
lymphocyte responses | 15 |
mediated innate | 15 |
nipah virus | 15 |
major cause | 15 |
takes place | 15 |
antiviral agents | 15 |
gene transfer | 15 |
inflammatory molecules | 15 |
cd memory | 15 |
chronic hiv | 15 |
affinity maturation | 15 |
mediated type | 15 |
transmembrane protein | 15 |
produce high | 15 |
genetic predisposition | 15 |
i cards | 15 |
different subsets | 15 |
restriction element | 15 |
functional role | 15 |
graphpad software | 15 |
infected human | 15 |
express cd | 15 |
studies also | 15 |
producing il | 15 |
hospital admission | 15 |
chronic infections | 15 |
well known | 15 |
myeloid differentiation | 15 |
health outcomes | 15 |
immune sensor | 15 |
cytoplasmic tail | 15 |
horseradish peroxidase | 15 |
corticosteroid treatment | 15 |
intracellular dna | 15 |
newcastle disease | 15 |
high concentrations | 15 |
cells transfected | 15 |
sodium azide | 15 |
delivery system | 15 |
modified live | 15 |
corpus callosum | 15 |
virus strains | 15 |
final vaccine | 15 |
classical pathway | 15 |
still unknown | 15 |
tumor rechallenge | 15 |
vaccinated individuals | 15 |
bacterial species | 15 |
attenuated influenza | 15 |
recently identified | 15 |
i activity | 15 |
year follow | 15 |
severe inflammatory | 15 |
regulatory role | 15 |
tlr ligand | 15 |
demyelinating disease | 15 |
cdr length | 15 |
mouse hepatitis | 15 |
rbd protein | 15 |
rhesus macaque | 15 |
airway hyperresponsiveness | 15 |
lethal pneumonia | 15 |
lymphocyte activation | 15 |
clonal expansion | 15 |
disease onset | 15 |
mouse brain | 15 |
cells producing | 15 |
er stress | 15 |
prrs virus | 15 |
antitumor responses | 15 |
receptor alpha | 15 |
final volume | 15 |
antiviral signal | 15 |
female genital | 15 |
obtained using | 15 |
human immunoglobulin | 15 |
barrier functions | 15 |
symptom onset | 15 |
metastatic melanoma | 15 |
inhibitory effect | 15 |
vaccine construct | 15 |
chronic kidney | 15 |
germinal center | 15 |
neutrophil counts | 15 |
tissue distribution | 15 |
human subjects | 15 |
dry cough | 15 |
health status | 15 |
potential use | 15 |
effector responses | 15 |
disseminated intravascular | 15 |
neutrophilic inflammation | 15 |
i study | 15 |
mmr vaccination | 15 |
related diseases | 15 |
lung biopsies | 15 |
different mechanisms | 15 |
decreased levels | 15 |
infection human | 15 |
ill covid | 15 |
increases susceptibility | 15 |
naturally infected | 15 |
kupffer cells | 15 |
mice exhibited | 15 |
glycation end | 15 |
universal influenza | 15 |
much higher | 15 |
emerging viruses | 15 |
rna interference | 15 |
naive cd | 15 |
past years | 15 |
early pregnancy | 15 |
specific manner | 15 |
immunological potency | 15 |
mass cytometry | 15 |
cell lineages | 15 |
induced demyelination | 15 |
reduced levels | 15 |
significantly elevated | 15 |
clinical development | 15 |
inflammatory activity | 15 |
vascular leakage | 15 |
common feature | 15 |
will focus | 15 |
hemorrhagic fever | 15 |
replacement therapy | 15 |
preliminary results | 15 |
high doses | 15 |
new york | 15 |
receptor activation | 15 |
repertoire analysis | 15 |
spectrum antiviral | 15 |
cd cytotoxic | 15 |
polyubiquitin chains | 15 |
complement receptor | 15 |
storm syndrome | 15 |
physical exercise | 15 |
intracellular staining | 15 |
nasal epithelial | 15 |
lymphocyte counts | 15 |
serum albumin | 15 |
stress response | 15 |
observational studies | 15 |
chain fatty | 15 |
viral spread | 15 |
responses via | 15 |
dysregulated immune | 15 |
five types | 15 |
major infection | 15 |
cytotoxic lymphocytes | 15 |
mortality associated | 15 |
coding potential | 15 |
fully understood | 15 |
negatively correlated | 15 |
observations suggest | 15 |
alpha interferon | 15 |
immunity via | 14 |
induced cytokine | 14 |
bbb permeability | 14 |
envelope protein | 14 |
heavy chains | 14 |
body mass | 14 |
viral nucleic | 14 |
increasing number | 14 |
host antiviral | 14 |
patients undergoing | 14 |
interferon receptor | 14 |
positive bacteria | 14 |
induced arthritis | 14 |
mapk signaling | 14 |
rainbow trout | 14 |
receptor agonist | 14 |
two major | 14 |
plantarum group | 14 |
polymerase ii | 14 |
cells represent | 14 |
immunological memory | 14 |
provide new | 14 |
inhibitory molecules | 14 |
dppiv inhibitors | 14 |
immunocytokine comprised | 14 |
epitope prediction | 14 |
specific th | 14 |
adenosine deaminase | 14 |
mediated ifn | 14 |
clinical improvement | 14 |
acute myocardial | 14 |
cells isolated | 14 |
macrophages may | 14 |
induced complete | 14 |
acid residues | 14 |
healthcare workers | 14 |
tumor cell | 14 |
human interleukin | 14 |
typeable haemophilus | 14 |
broad range | 14 |
cell lysis | 14 |
large scale | 14 |
adult patients | 14 |
increased cd | 14 |
incubation period | 14 |
acute influenza | 14 |
human antibody | 14 |
immune protection | 14 |
reactive antibodies | 14 |
pol ii | 14 |
standard care | 14 |
coronavirus replication | 14 |
inflammasome signaling | 14 |
mediated lung | 14 |
emerging role | 14 |
antibody repertoires | 14 |
health commission | 14 |
adoptively transferred | 14 |
sialic acid | 14 |
will help | 14 |
mers coronavirus | 14 |
different species | 14 |
avian leukosis | 14 |
endothelial dysfunction | 14 |
quality control | 14 |
immunized groups | 14 |
increased lung | 14 |
remains unknown | 14 |
live vaccine | 14 |
signaling events | 14 |
free dna | 14 |
campylobacter infection | 14 |
ibalt mice | 14 |
rsv vaccine | 14 |
peptide peptidase | 14 |
whitney test | 14 |
csf receptor | 14 |
tobacco smoke | 14 |
interstitial pneumonia | 14 |
protein antigens | 14 |
expressing interleukin | 14 |
inactivated virus | 14 |
rhesus monkeys | 14 |
severe rsv | 14 |
tlr stimulation | 14 |
intravascular coagulation | 14 |
phage display | 14 |
nucleolus nexus | 14 |
including tnf | 14 |
influenza infections | 14 |
virus assembly | 14 |
macrophage phenotype | 14 |
genes upregulated | 14 |
like disease | 14 |
human clinical | 14 |
lower mortality | 14 |
inhibit rig | 14 |
next generation | 14 |
antiphospholipid syndrome | 14 |
type lectins | 14 |
inkt cells | 14 |
biological activity | 14 |
cell count | 14 |
hela cells | 14 |
maternal antibodies | 14 |
mouse monoclonal | 14 |
local inflammation | 14 |
oppa protein | 14 |
current evidence | 14 |
human umbilical | 14 |
rgnnv infection | 14 |
tumour necrosis | 14 |
therapeutic effects | 14 |
phase study | 14 |
pathogenic coronaviruses | 14 |
atherosclerotic plaques | 14 |
last decade | 14 |
prospective cohort | 14 |
inhibitory receptor | 14 |
inflammatory protein | 14 |
immune defenses | 14 |
bnp cows | 14 |
cd alpha | 14 |
stimulatory mer | 14 |
signal sequence | 14 |
endosomal tlrs | 14 |
responses cause | 14 |
possible explanation | 14 |
novel therapeutic | 14 |
fatty acylation | 14 |
signaling molecules | 14 |
pneumoniae infection | 14 |
adcc activity | 14 |
cd low | 14 |
immunization groups | 14 |
cell recognition | 14 |
cytopathic effect | 14 |
coe protein | 14 |
like symptoms | 14 |
drug delivery | 14 |
mucociliary clearance | 14 |
repressor domain | 14 |
attenuated strain | 14 |
central memory | 14 |
cd dendritic | 14 |
acylated proteins | 14 |
treated patients | 14 |
specific ctl | 14 |
intravenous immunoglobulins | 14 |
infectious agents | 14 |
immune modulation | 14 |
chain il | 14 |
specific pathogen | 14 |
induced cd | 14 |
results demonstrated | 14 |
spotted grouper | 14 |
responses induced | 14 |
conjugated secondary | 14 |
different immune | 14 |
infected cell | 14 |
positive patients | 14 |
induce ifn | 14 |
also inhibit | 14 |
antibodies may | 14 |
independent manner | 14 |
obese mice | 14 |
bv cells | 14 |
rat model | 14 |
group innate | 14 |
complement activity | 14 |
bat origin | 14 |
sex hormone | 14 |
reproductive tract | 14 |
balb cj | 14 |
kd patients | 14 |
cytokines like | 14 |
intracellular bacteria | 14 |
laboratory animals | 14 |
epitope vaccine | 14 |
independent pathways | 14 |
fulminant hepatitis | 14 |
immunological response | 14 |
therapeutic efficacy | 14 |
vaginal lactobacilli | 14 |
relative abundance | 14 |
proven protease | 14 |
weeks old | 14 |
responses may | 14 |
dependent cellular | 14 |
related coronavirus | 14 |
will allow | 14 |
iuis vic | 14 |
descriptive study | 14 |
factor kappa | 14 |
mainly due | 14 |
considered significant | 14 |
long term | 14 |
maternal immune | 14 |
leukosis virus | 14 |
flow cytometer | 14 |
flox control | 14 |
national institutes | 14 |
tumor models | 14 |
airway mucosa | 14 |
response may | 14 |
santa cruz | 14 |
protein sequence | 14 |
study identified | 14 |
entry depends | 14 |
clinical relevance | 14 |
cytotoxicity assay | 14 |
lectin receptors | 14 |
danger signals | 14 |
first report | 14 |
blood igm | 14 |
viral defenses | 14 |
bacillus calmette | 14 |
cd th | 14 |
mediated rig | 14 |
cell hyperplasia | 14 |
bulk cd | 14 |
viral activity | 14 |
severe asthma | 14 |
cell lung | 14 |
peripheral immune | 14 |
ulcerative colitis | 14 |
cause lethal | 14 |
visceral leishmaniasis | 14 |
deficient cells | 14 |
extracellular domain | 14 |
secrete il | 14 |
healthy subjects | 14 |
basal levels | 14 |
complement component | 14 |
times post | 14 |
immunoglobulin preparations | 14 |
adaptor proteins | 14 |
fatty liver | 14 |
centromeric instability | 13 |
functional properties | 13 |
monocyte chemoattractant | 13 |
stat phosphorylation | 13 |
liver injury | 13 |
within il | 13 |
duck plague | 13 |
pcr amplification | 13 |
programmed cell | 13 |
cellular infiltration | 13 |
rna extraction | 13 |
increased serum | 13 |
scd levels | 13 |
progenitor cell | 13 |
soluble cd | 13 |
significantly upregulated | 13 |
particularly important | 13 |
inversely correlated | 13 |
neutrophil function | 13 |
cells specific | 13 |
immunology approach | 13 |
independent mechanisms | 13 |
induced activation | 13 |
helicobacter pylori | 13 |
earlier studies | 13 |
protein complex | 13 |
toolkit workshop | 13 |
early childhood | 13 |
induce apoptosis | 13 |
disease outcome | 13 |
ap activation | 13 |
interferon expression | 13 |
malaria infection | 13 |
mice challenged | 13 |
direct effects | 13 |
ii trial | 13 |
rhamnosus crl | 13 |
results suggested | 13 |
positive pd | 13 |
publicly available | 13 |
cell suspensions | 13 |
provide novel | 13 |
wound repair | 13 |
risk populations | 13 |
including sars | 13 |
variable region | 13 |
ii binding | 13 |
hemolytic anemia | 13 |
protein docking | 13 |
derived il | 13 |
respiratory epithelium | 13 |
severe iav | 13 |
authors showed | 13 |
proteomic analysis | 13 |
health concern | 13 |
activated platelets | 13 |
mice vaccinated | 13 |
based therapies | 13 |
dpp family | 13 |
secreting cells | 13 |
genes encoding | 13 |
pb nk | 13 |
treat covid | 13 |
mediated mechanisms | 13 |
pancreatic cancer | 13 |
binding activity | 13 |
receptor stimulation | 13 |
experimentally infected | 13 |
ciliated cells | 13 |
coronavirus papain | 13 |
hfri approach | 13 |
chronic respiratory | 13 |
rank test | 13 |
human epithelial | 13 |
global burden | 13 |
placental barrier | 13 |
complex formation | 13 |
culture conditions | 13 |
unfolded protein | 13 |
mhc ii | 13 |
may still | 13 |
enhanced viral | 13 |
severe infections | 13 |
sense rna | 13 |
potential mechanism | 13 |
data demonstrate | 13 |
sample size | 13 |
treated cells | 13 |
glial cells | 13 |
commercial vaccine | 13 |
tight junction | 13 |
atp hydrolysis | 13 |
influenza hemagglutinin | 13 |
tightly regulated | 13 |
protect mice | 13 |
existing comorbidities | 13 |
diffuse alveolar | 13 |
organ damage | 13 |
mouse sera | 13 |
traumatic brain | 13 |
pulmonary embolism | 13 |
last years | 13 |
inflammatory environment | 13 |
papilloma virus | 13 |
different pathogens | 13 |
evasion mechanisms | 13 |
induced trained | 13 |
washed three | 13 |
human studies | 13 |
systemic administration | 13 |